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Abstract 
Background: Persistent methamphetamine (METH) psychosis is a psychotic state beyond 1-month after 
abstinence, for which there is no effective treatment. This study aimed to evaluate the effectiveness of 
electroconvulsive therapy (ECT) in persistent METH psychosis patients hospitalized at Shahid Beheshti 
Hospital, Kerman, Iran, from 6 September 2012 until 6 September 2013, who were not remitted after 
treatment with olanzapine. 
Methods: This research was a pilot study on hospitalized patients. After 4 weeks of treatment with 
olanzapine, 10 out of 71 studied patients did not show complete remission of psychotic symptoms despite 
their response to the treatment. The mentioned 10 patients were divided into 2 groups by random digit 
numbers. 5 patients had continued olanzapine and other 5 received 6 sessions of bilateral ECT every other 
day in addition to olanzapine. 
Findings: Remission rate of patients in the initial 4 weeks was 78.7%. Reduction in total brief psychiatric 
rating scale (BPRS) scale at the end of 1-week compared with the next week demonstrated improvement in 
the symptoms until the end of the study. There was no significant difference in BPRS scores between weeks 4 
and 6 in the two groups. 
Conclusion: This research demonstrated that few sessions of ECT in persistent METH psychosis will not lead 
to remission in all patients. 
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Introduction 
Illicit methamphetamine (METH) abuse is a 
serious health and social concern in many 
countries worldwide, including Iran. In Iran, a 
transition is happening from traditional patterns 
of using opium and opium residue to METH 
abuse,1 which was rare in the past decades2 but is 
significantly growing in the recent years,1,3 
especially among the youth.4 Some pieces of 
evidence are available for the rapid increase of 
METH abuse in Iran since 2008, the substantial 
portion of which is originated from small 
laboratories.5 Although no definite estimation 
exists about the prevalence and incidence of 
METH abuse in Iran, some reports have identified 
it as the second most prevalent substance in the 
country.5 
Amphetamines are widely prescribed for 
conditions such as attention deficit hyperactivity 
disorder with very little risk of psychosis.6,7 In 
contrast, illicit use of METH, especially in 
supratherapeutic doses taken by the non-oral 
routes of administration can cause psychotic 
symptoms more frequently.8 
Persistent METH psychosis (beyond 1-month 
after abstinence) has been extensively observed in 
Japan for more than 50 years; however, it is rarely 
discussed in the American literature, possibly 
because some of such cases are misdiagnosed in 
the United States as primary psychotic disorders. 
This issue is reflected in the diagnostic lexicon of 
Diagnostic and Statistical Manual of Mental 
Disorders-4th Edition (DSM-IV), which defines 
substance-induced psychosis to be persistent for 
1-month or less after the last substance use.9 Until 
recently, Japanese substance abusers have rarely 
consumed drugs other than METH; thus, 
investigators could assess the effects of METH 
without the confounding effects of other 
substances.10 Considering the growing public 
health problem of METH abuse in many countries 
in the world, the distinction between persistent 
METH psychosis and a primary psychotic 
disorder has become increasingly important.11 
As mentioned above, most of the voluminous 
international literature on METH psychosis has 
occurred in Japan and Japanese studies have 
frequently reported discouraging results with 
standard antipsychotic drugs.12 One case report of 
electroconvulsive therapy (ECT) in METH 
psychosis treatment is entitled “remission of 
persistent METH-induced psychosis after ECT;” 
however, to the best knowledge of the present 
authors, no other studies have been conducted in 
this regard thus far; only one work has 
demonstrated the effects of repeated 
electroconvulsive shock (ECS) on METH-induced 
behavioral abnormalities in mice.13 ECT is 
considered for the treatment of refractory 
psychosis regardless of the diagnosis and has 
been shown to be effective among the patients 
with refractory psychotic symptoms associated 
with major depression, bipolar disorder, 
Huntington chorea, Parkinson’s disease, and 
vascular depression among other disorders.14 
In this center, ECT was being used in the 
treatment of METH psychosis. According to the 
above reasons, this study was done to evaluate 
the effectiveness of ECT in persistent METH 
psychosis. As a result, clinicians must be alert to 
the possibility of persistent METH psychosis 
and wish to consider ECT in refractory cases; 
thus, after remission, the patients would return 
to their full baseline level of social and 
occupational functioning. 
Persistent METH psychosis is defined as a 
psychotic state beyond 1-month after abstinence, 
for which there is no effective treatment. The 
present work aimed to evaluate the efficacy of 
ECT in METH psychosis patients, who were not 
remitted after treatment with olanzapine. 
A recent Australian study which was done on 
277 non-treatment-seeking illicit METH users 
with no prior diagnosis of schizophrenia or other 
psychotic disorders demonstrated that 51 (18.0%) 
had “clinically significant” psychotic symptoms.8 
Similarly, a recent U.S. work on 42 cocaine-
dependent and 43 METH-dependent individuals, 
which aimed to exclude patients with other axis I 
disorders, reported psychotic symptoms of at 
least some type among at least 60.0% of both 
groups.12 Although recent studies have noted the 
limitations in definition and diagnosis and the 
variety of studied populations, they have shown 
that between 26.0 and 46.0% of people with 
METH dependence have psychotic symptoms.9 
Smoking and injection are the main routes of 
METH abuse;5 it seems that smoking is the most 
common route of METH abuse in Iran. 
Multiple studies in Japanese,15 Taiwanese,16 
Australian,17 and Thai10 populations have 
reported high frequency of persecutory delusions 
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and auditory hallucinations among people with 
METH psychosis. Delusions of reference, visual 
hallucinations, and thought broadcasting are 
other frequently reported symptoms.10,15,16 In a 
study on 149 METH abusers, mean latency of the 
first use of METH to the onset of psychosis was 
5.2 years; another work compared METH injectors 
and smokers and observed the latency of 4.4 years 
in injectors and 1.7 years for smokers.11 
Although psychotic symptoms usually remit 
after acute intoxication, some patients have 
exhibited prolonged psychosis for weeks or 
months after stopping METH.9 In a Japanese 
study, 52.0% of 104 hospitalized METH users with 
METH psychosis psychotic symptoms abated 
within 1-week; in contrast, 26.0% had symptoms 
that persisted for more than 1-month and 16.0% of 
their symptoms persisted for more than 3 months 
of abstinence.18 In a Taiwanese work, which was 
performed on 174 hospitalized METH users with 
METH psychosis, 17.0% of symptoms persisted 
for more than 1-month of abstinence.16 
Japanese investigators have mentioned three 
types of METH psychosis based on the time 
course after abstinence: Transient type with brief 
duration (duration < 1-week), prolonged type in 
which psychotic state continues up to 1-month of 
last METH use, and persistent type that is 
represented with psychotic state beyond 1-month 
after abstinence.15 Japanese researchers have 
estimated that 40.0% of various types of METH 
psychosis suffer from the persistent type.15,17 
There are few works on METH psychosis 
treatment. One early Japanese study described 74 
patients with METH psychosis observed prior to 
the era of neuroleptics, in which about two-third 
of the patients remitted within 20 days after 
stopping METH, but about 10.0% displayed 
psychosis, which lasted for more than 6 months 
and in some cases even a few years.19 
In another early study, Teraoka reported 
“schizophrenia-like symptoms” in 32 (28.0%) out 
of 114 former METH users who were followed up 
after 8-12 years.20 A more recent investigation 
described 132 consecutive patients with METH 
psychosis who admitted to a Tokyo hospital from 
1978-1987; about 28.0% of them required more 
than 61 days of hospitalization.21 A subsequent 
report from the same group described 104 
additional patients with METH psychosis 
admitted to the same hospital from 1988-1991; 
despite abstinence from METH and 
administration of antipsychotic drugs, 16 (15.0%) 
required more than 3 months of hospitalization.18 
A more recent Japanese work in another center 
observed that 28.0% of inpatients with METH 
psychosis had symptoms that persisted for longer 
than 6 months of abstinence.18 
Similarly, Akiyama mentioned 32 female 
prisoners treated with standard antipsychotic 
medications for METH psychosis, none of whom 
were reported to have displayed psychosis or a 
diagnosis of schizophrenia prior to METH use. As 
prisoners, the women had no access to further 
METH. Although the exact number of those who 
did and did not respond to the treatment could 
not be calculated from the article, it appears that a 
majority of patients, especially those with more 
severe symptoms, were still symptomatic even 
after many months of antipsychotic treatment.15 
Paucity of research in the area of treatment of 
METH psychosis was highlighted by a 2008 
Cochrane Review22 that found only one 
randomized controlled trial of the treatment of 
amphetamine psychosis in the related literature, 
which was a 4 weeks investigation on 58 patients 
with amphetamine psychosis in Thailand.23 There 
was no significant difference in terms of clinical 
efficacy between olanzapine and haloperidol and 
27 (93.0%) out of 29 patients on olanzapine and 23 
(79.0%) out of 29 patients on haloperidol had at 
least 40.0% improvement on brief psychiatric 
rating scale (BPRS) after 4 weeks; however, it was 
not clear how many patients still exhibited 
psychotic symptoms at the endpoint. 
Furthermore, because of the lack of placebo arm, 
it is difficult to judge if improvement is the 
natural course of amphetamine psychosis alone or 
not. Two recent case reports have separately 
found olanzapine24 and risperidone25 to be 
effective for METH psychosis. Because ECT has 
not been widely used in Japanese psychiatry, 
Japanese literature lacks ECT trials of METH 
psychosis.9 
Methods 
The present study was designed as a randomize 
control trial with 42 sample size out of 105 METH 
psychosis. It was performed on hospitalized 
patients from September 6, 2012 to September 6, 
2013 at Shahid Beheshti Hospital, Kerman, Iran. It 
was supported by Research Center for Science 
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and Neurology under the ethical code of 
K/93/95. 
For collecting the sample size, the study with 
olanzapine was started; the reason for choosing 
olanzapine as the anti-psychosis drug was related 
to the only randomized controlled trial research 
conducted in Thailand, in which 93.0% of patients 
showed at least 40.0% reduced symptoms based 
on BPRS.23 
After admission of the patients who were 
diagnosed to have METH psychosis confirmed 
using positive METH test, a DSM-IV-based semi-
structured interview was conducted to confirm 
the initial diagnosis; then, exclusion criteria were 
reviewed: Positive family history of mood or 
psychotic disorders (e.g. bipolar and 
schizophrenia) among first and second degree 
relatives, physical diseases such as diabetes and 
epilepsy requiring medical treatment, and being 
depended or abusing other substances including 
cannabis and benzodiazepines, but not opium, 
because most patients were opium consumers and 
the sample of this study would not be collected 
during the anticipated duration (1-year).  
After 1-year from the beginning of the study, 
71 patients entered the study and, out of these  
71 patients, 24 patients left the study. Out of  
47 (instead of 105) patients who were remained 
and received 4 weeks of treatment with 
olanzapine, 37 patients were recovered and  
10 psychotic (instead of 42) patients were 
remained for the trial (based on the score of 
higher than 4 in each of psychotic subgroup items 
of BPRS questionnaire). The patients were 
assigned to two groups using random digit 
numbers; in the first group, drug prescription was 
continued and, in the second group, 6 sessions of 
bilateral ECT were added to the drug intake every 
other day for 2 weeks (Figure 1). Maximum length 
of hospitalization was 6 weeks and BPRS 
questionnaire was filled for 7 times to assess the 
patients’ symptoms (at baseline and then once per 
week until the end of week 6). 
Why the sample size was small in this study? 
Two responses can be mentioned as follows: 
• In this work, persistent METH psychosis was 
approximately 21.0% [i.e. half of what Japanese 
investigators reported (40.0%)] 
• Another reason for the small sample size was 
34.0% dropout, 20.0% (n = 14) of which was due to 
early discharge of patients by their families because 
of either partial and/or lack of response to the 
treatment that can be a confounding factor. 
Moreover, in 3.0% (n = 2) of the cases, the physician 
started ECT earlier than 1-month from the start of 
the treatment due to their intensity of symptoms. 
8.0% (n = 6) of the data loss was related to lack of 
coordination of the treatment team and the point 
that more than one physician visited the patients at 
the education hospital. It seems that better declare of 
information before the study could reduce this 8.0% 
of dropout. The remaining 3.0% (n = 2) of data loss 
was because of drug reaction (delirious state). 
• Due to the small sample size, the 
investigation was considered to be a pilot study. It 
is well-known that pilot studies are a necessary 
first step in exploring novel interventions and 
novel applications of interventions and their 
purpose is to examine the feasibility of an 
approach and point out the modifications 
required for planning and designing a larger 
efficacy trial. Pilot studies can be used in all types 
of studies such as randomized control trials.26 
• Demographic variables of the patients (age, 
sex, marital status, educational level, occupation, 
and onset of METH abuse) were compared 
between the two groups (Table 1). BPRS which 
gives ratings of 1 (absent) to 7 (extremely severe) 
for each item was filled to evaluate the patients’ 
symptoms. This scale has been translated into 
Persian and was utilized in study of Fallahi.27 
Reliability coefficient of the tool has been 
determined by Chronbach’s alpha as r = 0.80 in 
some studies. For measuring response to the 
treatment, the scores of the 18 items were summed 
and the total score was recorded. Then, the total 
score from one evaluation was compared with that 
of the next.28 
Olanzapine and buprenorphine were 
administered for the patients with psychotic 
symptoms and addiction, respectively. Also, 
antidepressant and mood stabilizers were 
administered for the patients with severe mood 
disorders due to METH. Prescribing 
antidepressants and mood stabilizers can be a 
confounding factor. To remove its effect, it was 
better to compare people who received this drug 
with those who did not. However, such a 
comparison was not made in this investigation. 
Except olanzapine, no other antipsychotic 
drugs were used. Olanzapine started with 5-10 mg 
and continued up to the maximum 20 mg as rapidly 
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Figure 1. Organizational chart showing the patients’ entrance into the study 
METH: Methamphetamine; ECT: Electroconvulsive therapy 
 
as possible in 1-week. Finally, all of the patients 
received 20 mg of olanzapine in both groups. 
Although a better response can be observed at 
higher doses, olanzapine dose was not increased 
to more than this amount due to increased 
probability of its complications. It should be 
mentioned that, the aim of olanzapine treatment 
was to spend 1-month without taking METH, 
since according to ethical considerations and 
hospitalization limitations, the patient with 
psychotic symptoms could not be hospitalized 
without any medications. 
71 patients entered the study
47 patients remained in the study
10 patients METH psychotic entered second 
phase of study
5 patients drug  was continued 5 patients ECT was added to the drug
37 patients recovered
24 patients dropped out :
1- 14 patients were discharged  by 
their family with personal satisfaction
2- 6 patients were discharged by their 
physicians
3- 2 patients started ECT before week 
4 by their doctors
4- 2 patients had delirious state  
undetermined number excluded 
patients because of exclusion 
criteria
Undetermined number of 
patients diagnosed as METH 
psychosis 
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Categorical and quantitative data were 
compared between the two groups using  
chi-square and independent t-test. Two-way 
repeated-measures ANOVA was also used to 
compare the course of treatment outcome along 
the 6 weeks of the study. 
Similar to other trials, this study had several 
limitations: The first and main limitation of the 
present study was small sample size due to the 
failure in sample collection and lack of remission 
after ECT in all the cases (5 patients) of this study 
was confounded with small sample size. A pilot 
study is not a hypothesis-testing study and safety, 
efficacy, and effectiveness are not evaluated in a 
pilot work. Thus, this pilot study cannot 
determine the rate of remission after ECT, but 
offers little insight into lack of remission after ECT 
in all persistent cases. 
Second limitation: It should be considered 
that some of the patients’ symptoms might have 
been attributable to an underlying primary axis 
I disorder. 
To reduce such likelihood, the patients who 
had positive family histories of schizophrenia or 
bipolar disorders were not enrolled the study. In 
addition, the present patients showed good 
academic and occupational functioning prior to 
regular METH smoking. Also, psychotic 
symptoms appeared after long term use, a pattern 
which could indicate amphetamine-associated 
neurotoxic effects. The latency from the first 
METH smoking to the onset of psychosis was 3.5 
years, similar to other studies. In Matsumoto et 
al.’s study, it was 1.7 years [standard deviation 
(SD) = 2.0] among smokers and 4.4 years in 
injectors.29 Also, it was 5.2 years in the study by 
Ujike and Sato.17 Considering the above 
chronology, illicit METH smoking appears to be 
the most parsimonious explanation for the 
etiology of the symptoms. 
Moreover, in Iran similar to other countries, 
there are a considerable number of multi-drug 
abusers; thus in this study, cannabis and/or 
benzodiazepine abusers were excluded. However, 
there is a traditional pattern of using opium and 
opium residue in Iran which could not be 
excluded. Because equal number of patients in 
both groups consumed opium, this issue cannot 
be a confounding factor, but could raise the 
following question for the present authors: 
Whether using opium by these patients plays a 
role in the remission failure after ECT or not. 
Results 
As depicted in table 1, demographic characteristics 
were not significantly different between the two 
groups. Mean age ± SD for the members of drug 
group was 36.6 ± 4.9 years, while it was 39.4 ± 11 
years for drug + ECT group (P = 0.618). Duration of 
using METH for the members of drug group was 
43.2 ± 24.9 months, while it was 40.8 ± 10.7 months 
for drug + ECT group (P = 0.848). Number of 
patients with part-time jobs (% within group) was 2 
(40.0%) and the unemployed was 3 (60.0%) in drug 
group, whereas they were 1 (20.0%) and 4 (80.0%) 
in drug + ECT group, respectively (P > 0.050). In 
terms of education, 2 (40.0%) were below high 
school diploma and 3 (60.0%) had high school 
diploma in drug group, while they were 1 (20.0%) 
and 4 (80.0%) in drug + ECT group, respectively  
(P > 0.050). 
Figure 2 indicates that there was no 
statistically significant difference in response to 
treatment between the two groups that is 
demonstrated with non-significant P = 0.167 for 
between-subject effect and 0.784 for interaction.  
P-value for within-subject effect was significant  
(< 0.001). There was no significant difference 
between mean BPRS score at the end of weeks 4 
(37.4 ± 13.1 vs. 36.0 ± 9.7) (P = 0.852) and  
6 (30.8 ± 5.7 vs. 30.2 ± 7.4) (P = 0.890) in one group 
with the same scores in the other group. In other 
 
Table 1. Comparing demographic variables in both groups 
Demographic variables Drug Drug + ECT P 
Age (year) (mean ± SD) 36.6 ± 4.9 39.0 ± 11.0 0.618 
Duration of consumption (month) (mean ± SD) 43.2 ± 24.9 40.8 ± 10.7 0.848 
Job (within group) [n (%)] Unemployed 3 (60) 4 (80) > 0.050 Part time 2 (40) 1 (20) 
Education (within group) [n (%)] Under diploma 2 (40) 1 (20) > 0.050 Under diploma 3 (60) 4 (80) 
SD: Standard deviation; ECT: Electroconvulsive therapy 
ECT in Persistent Methamphetamine Psychosis Ziaaddini et al. 
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Figure 2. BPRS (brief psychiatric rating scale) scores of 6 weeks of treatment in two groups 
ECT: Electroconvulsive therapy; BPRS: Brief psychiatric rating scale 
 
words, in this preliminary clinical trial, remission 
was not observed for ECT. In the present work, 
mean latency from the first METH abuse to the 
onset of psychosis was about 3.5 years. 
Discussion 
To the best knowledge of the present authors, the 
current pilot study was the first work that evaluated 
ECT in persistent METH psychosis (psychosis which 
is prolonged to more than 1 month after abstinence). 
In none of the 5 studied patients treated with 
olanzapine and none of the 5 patients treated with 
olanzapine plus 6 sessions of bilateral ECT, 
remission was observed. There was no statistically 
significant difference in response to treatment 
between the two groups but P-value for within-
subject effect was significant (< 0.001); i.e. reduction 
in total BPRS scale at the end of 1-week compared 
with the next week demonstrated improvement in 
the symptoms until the end of the study.  
Our finding was unlike the remission that was 
seen after 6 sessions of right unilateral ECT in a 
case report among persistent METH psychosis 
from Massachusetts. The mechanism through 
which ECT might benefit METH psychosis is still 
speculative. However, it should be noted that 
striatal dopamine is reduced in rhesus monkeys30 
and rodents31,32 exposed to METH along with the 
postmortem tissues from people with METH 
addiction.33 Conversely, chronic ECS increases 
striatal dopamine in healthy rats.34,35 
Neuroimaging findings in chronic METH users 
have demonstrated a decrease in dopamine 
transporters that recovers only gradually after 
prolonged abstinence, suggesting dopamine 
terminal damage which is very slow to repair.36 
Recent animal data have recommended that 
chronic METH exposure leads to decreased 
immediate early gene (e.g., c-fos) expression.37 
In contrast, ECS is associated with increased 
brain-derived neurotropic factor, nerve growth 
factor, and immediate early gene (e.g., c-fos) 
expression; therefore, ECT may confer 
neuroprotection and neuroplasticity.35 Thus, it can 
be speculated that ECT counteracts the effects of 
METH, at least partially through normalization of 
the neural environment or by stimulating the 
proliferation of nerve terminals. However, 
extrapolation from animal studies must be 
cautiously done, since such studies may use larger 
amphetamine doses than those used by humans 
and may not mimic the gradual escalation of 
dosage typical in human abusers, which is a 
pattern that may attenuate amphetamine-
associated neurotoxic effects.32  
Results of this investigation revealed that few 
sessions of ECT in persistent METH psychosis will 
not lead to remission in all patients. Furthermore, it 
is not clear if increasing ECT sessions may lead to 
remission, at least in a greater number of patients, 
ECT in Persistent Methamphetamine Psychosis Ziaaddini et al. 
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or not, because it is speculated that ECT 
counteracts the effects of METH, at least partially, 
through normalization of the neural environment 
or by stimulating the proliferation of nerve 
terminals, which may require more ECT sessions. It 
is also essential to conduct studies with a large 
enough sample size and increase the number of 
ECT sessions to evaluate remission rate after ECT 
in persistent METH psychosis, because safety, 
efficacy, and effectiveness cannot be evaluated in 
pilot studies.26 
Conclusion 
This research demonstrated that few sessions of 
ECT in persistent METH psychosis will not lead 
to remission in all patients. Therefore, it is 
essential to conduct further investigations with a 
large enough sample size and increase the 
number of ECT sessions to evaluate the 
effectiveness of ECT because safety, efficacy, and 
effectiveness cannot be evaluated in pilot studies; 
and increase the number of ECT sessions in order 
to it is not clear if increasing ECT sessions may 
lead to remission or not. 
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